Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Hellmann

Showing results (121-130 of 172) with videos related to

Pageof 18
Sort By:
Cell|January 28, 2021
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionKevin Litchfield, James L Reading, Clare Puttick, et al.
Nature|March 22, 2019
Neoantigen-directed immune escape in lung cancer evolutionRachel Rosenthal, Elizabeth Larose Cadieux, Roberto Salgado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerRohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Leora Horn, David R Spigel, Everett E Vokes, et al.
Cancer Discovery|September 1, 2022
Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing CohortKanika Arora, Thinh N Tran, Yelena Kemel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 TherapyJarushka Naidoo, Xuan Wang, Kaitlin M Woo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLCScott J Antonia, Ani Balmanoukian, Julie Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2018
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation SequencingHira Rizvi, Francisco Sanchez-Vega, Konnor La, et al.
Cancer Immunology Research|December 18, 2023
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota TransplantationArielle Elkrief, Nicholas R Waters, Natalie Smith, et al.
Nature|May 31, 2022
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Pageof 18

Showing results (121-130 of 172) with videos related to

Sort By:
Pageof 18
Cell|January 28, 2021
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionKevin Litchfield, James L Reading, Clare Puttick, et al.
Nature|March 22, 2019
Neoantigen-directed immune escape in lung cancer evolutionRachel Rosenthal, Elizabeth Larose Cadieux, Roberto Salgado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerRohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Leora Horn, David R Spigel, Everett E Vokes, et al.
Cancer Discovery|September 1, 2022
Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing CohortKanika Arora, Thinh N Tran, Yelena Kemel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 TherapyJarushka Naidoo, Xuan Wang, Kaitlin M Woo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLCScott J Antonia, Ani Balmanoukian, Julie Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2018
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation SequencingHira Rizvi, Francisco Sanchez-Vega, Konnor La, et al.
Cancer Immunology Research|December 18, 2023
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota TransplantationArielle Elkrief, Nicholas R Waters, Natalie Smith, et al.
Nature|May 31, 2022
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Pageof 18